Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.73 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10016378 | 0.86 | NPC1 (0.76) | NPC1RAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL425769 | 0.86 | MEN1 (0.77) | NPC1RAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL428619 | 0.85 | MEN1 (1.00) | NPC1RAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL19000066 | 0.84 | RAB9A (0.82) | NPC1RAB9AMEN1KMT2ACHRM4 | |
| SCHEMBL23695577 | 0.82 | RAB9A (1.00) | NPC1RAB9AMEN1KMT2ACHRM4 | |
| SCHEMBL430266 | 0.81 | MEN1 (0.72) | NPC1RAB9AMEN1KMT2ACHRM4 | |
| SCHEMBL425768 | 0.80 | RAB9A (0.78) | NPC1RAB9AMEN1KMT2ACHRM4 | |
| SCHEMBL13186382 | 0.80 | RAB9A (0.72) | NPC1RAB9AMEN1KMT2ACHRM4 | |
| SCHEMBL424850 | 0.80 | NPC1 (0.75) | NPC1RAB9AMEN1KMT2ACHRM4 | |
| SCHEMBL14650720 | 0.80 | NPC1 (0.66) | NPC1RAB9AMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140255386-A1 | MICRORNA MODULATORS AND METHOD FOR IDENTIFYING AND USING THE SAME | NORTH CAROLINA STATE UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2014089378-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013019469-A1 | MICRORNA MODULATORS AND METHOD FOR IDENTIFYING AND USING THE SAME | THE WISTAR INSTITUTE (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120010177-A1 | MicroRNA Modulators and Method for Identifying And Using The Same | The Wistar Institute / North Carolina State University (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010177-A1 | MicroRNA Modulators and Method for Identifying And Using The Same | The Wistar Institute / North Carolina State University (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100196357-A1 | Microrna modulators and method for identifying and using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-05 | — | — | US | disclosed |
| US-20100196357-A1 | Microrna modulators and method for identifying and using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | NPC1 2091/4885RAB9A 1654/4885MEN1 3284/4885 |
| US-20100196357-A1 | Microrna modulators and method for identifying and using the same | AGO2, RNASE1, TRDMT1 | NPC1 667/4885RAB9A 2435/4885MEN1 1708/4885 |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | NPC1 1976/4885RAB9A 1518/4885MEN1 3532/4885 |
| US-20120010177-A1 | MicroRNA Modulators and Method for Identifying And Using The Same | AGO2, RNASE1, TRDMT1 | NPC1 667/4885RAB9A 2435/4885MEN1 1708/4885 |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | NPC1 1976/4885RAB9A 1518/4885MEN1 3532/4885 |
| US-20140255386-A1 | MICRORNA MODULATORS AND METHOD FOR IDENTIFYING AND USING THE SAME | AGO2, RNASE1, TRDMT1 | NPC1 667/4885RAB9A 2435/4885MEN1 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.